Preparation and Characterization of a Polar Milk Lipid-enriched Component from Whey Powder.

Milk fat globule membrane (MFGM) is a lipid carrier in mammals including humans that consists mainly of polar lipids, like phospholipids and glycolipids. In this study, a process to enrich polar lipids in commercial butter and whey powder, including polar lipids of MFGM, was developed. WPC (whey protein concentrate) 60 was selected as the most suitable raw material based on the yield, phospholipid, protein, and lactose content of the polar lipid fraction obtained by ethanol extraction of two WPC (WPC60 and WPC70) and two buttermilk (A and B). After fractionation under optimum conditions, the polar-lipid enriched fraction from WPC60 contained 38.56% phospholipids. The content of glycolipids, cerebroside, lactosylceramide, ganglioside GM3, ganglioside GD3, was 0.97%, 0.55%, 0.09%, and 0.14%, respectively. Rancimat results showed that the oxidation stability of fish oil increased with an increase in the polar-lipid fraction by more than 30 times. In addition, the secretion of IL-6 and TNF-α decreased in a concentration-dependent manner after treatment of RAW 264.7 cells with 0.1 to 100 ppm of the polar lipid fraction. In this study, polar lipid concentrates with antioxidant and anti-inflammatory activity, were prepared from milk processing by-products. The MFGM polar lipid concentrates made from by-products are not only additives for infants, but are also likely to be used as antioxidants in cooking oils and as active ingredients for functional foods.

Pilot-scale demonstration of nitrogen recovery in the form of ammonium phosphate (AP) from anaerobic digestate.

Nitrogen in anaerobic digestate was recovered as ammonium phosphates (APs), a valuable fertilizer, in a pilot-scale system consisting of ammonia stripper, absorber and crystallizer. The dissolved ammonium concentration in the anaerobic digestate was stripped and then absorbed into the phosphoric acid (42.5 wt%) with 95% absorbing efficiency. As the NH3 stripping continued, both the N/P ratio and pH, key operating parameters in the absorber are optimized N/P = 0.6 and pH = 1.7. The residual AP solution after crystallization was reused to enhance the crystallization efficiency up to 88%. The overall recovery efficiency of APs was estimated at 72% of the input nitrogen mass. Analyses of SEM and XRD revealed that the recovered AP crystals were mainly composed of mono-ammonium phosphate (MAP). This pilot-scale study demonstrated that nitrogen load in anaerobic digestates could be effectively recovered as a valuable fertilizer source of AP crystals.

Methane utilization in aerobic methane oxidation coupled to denitrification (AME-D): theoretical estimation and effect of hydraulic retention time (HRT).

Even though aerobic methane-oxidation coupled to denitrification (AME-D) has been extensively studied, the exact estimation of CH4 utilization during this process still requires better understanding because effective utilization of CH4 is essential in denitrification performance, CH4 emission and economy. This study presents the effect of hydraulic retention time (HRT) on CH4 utilization in an AME-D bioreactor. Stoichiometries for AME-D were newly established by using the energy balance and the thermodynamic electron equivalent model. The theoretically determined CH4 utilized/NO3- consumed (C/N) ratio from the stoichiometry was 2.0. However, the C/N ratios obtained from the experiment varied with increasing tendency as the HRT increased. Specifically, the C/N ratio increased from 1.38 to 2.85 when the HRT increased from 0.5 to 1.0 days, which placed the theoretical C/N ratio at the HRT between 0.5 and 1.0 days. The higher C/N ratio at the longer HRT was associated with a larger CH4 utilization by methanotrophs than denitrifiers. The results obtained in this study together with those obtained in previous studies clearly illustrated that a variety of conditions affect the utilization of CH4 which is essential for optimizing the AME-D process.

Synergistic anticandidal activity of xanthorrhizol in combination with ketoconazole or amphotericin B.

Candida species are responsible for the fourth most common nosocominal bloodstream infection. Xanthorrhizol, a sesquiterpene compound isolated from Curcuma xanthorrhiza Roxb. has been reported to have anticandidal activity. The aim of this study is to investigate the synergistic anticandidal effect of xanthorrhizol in combination with ketoconazole or amphotericin B against Candida albicans, Candida glabrata, Candida guilliermondii, Candida krusei, Candida parapsilosis, and Candida tropicalis. Mostly, xanthorrhizol in combination with ketoconazole or amphotericin B exhibited the synergistic anticandidal effects against all species of Candida tested. In combination with xanthorrhizol, the concentration of ketoconazole or amphotericin B for inhibiting the growth of the tested Candida species could be reduced by >/=50%. Time-kill curves showed that 1/2 minimum inhibitory concentration (MIC) dose of xanthorrhizol, amphotericin B, or ketoconazole alone against each of the six Candida species did not inhibit the growth of all Candida species tested. However, 1/2 MIC dose of xanthorrhizol in combination with 1/2 MIC dose of ketoconazole or 1/2 MIC dose of amphotericin B exhibited growth inhibition of all Candida species tested and reduced viable cells by several logs within 4 h. These results support the potential use of xanthorrhizol as an anticandidal agent, and it can be used complementarily with other conventional antifungal agents.

Activity of panduratin A isolated from Kaempferia pandurata Roxb. against multi-species oral biofilms in vitro.

The formation of dental biofilm caused by oral bacteria on tooth surfaces is the primary step leading to oral diseases. This study was performed to investigate the preventive and reducing effects of panduratin A, isolated from Kaempferia pandurata Roxb., against multi-species oral biofilms consisting of Streptococcus mutans, Streptococcus sanguis and Actinomyces viscosus. Minimum inhibitory concentration (MIC) of panduratin A was determined by the Clinical and Laboratory Standards Institute (CLSI) broth microdilution assay. Prevention of biofilm formation was performed on 96-well microtiter plates by coating panduratin A in mucin at 0.5-40 microg/ml, followed by biofilm formation at 37 degrees C for 24 h. The reducing effect on the preformed biofilm was tested by forming the biofilm at 37 degrees C for 24 h, followed by treatment with panduratin A at 0.2-10 microg/ml for up to 60 min. Panduratin A showed a MIC of 1 microg/ml for multi-species strains. Panduratin A at 2 x MIC for 8 h exhibited bactericidal activity against multi-species planktonic cells for 8 h. At 8 x MIC, panduratin A was able to prevent biofilm formation by > 50%. Biofilm mass was reduced by > 50% after exposure to panduratin A at 10 microg/ml for 15 min. Panduratin A showed a dose-dependent effect in preventing and reducing the biofilm. These results suggest that panduratin A is applicable as a natural anti-biofilm agent to eliminate oral bacterial colonization during early dental plaque formation.